broad_id
string | depmap_id
string | ccle_name
string | screen_id
string | upper_limit
int64 | lower_limit
float64 | slope
float64 | r2
float64 | auc
float64 | ec50
float64 | ic50
float64 | name
string | moa
string | target
string | disease.area
string | indication
string | smiles
string | phase
string | passed_str_profiling
bool | row_name
string |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
BRD-K49328571-001-15-0 | ACH-000965 | RL952_ENDOMETRIUM | MTS010 | 1 | 1.741545 | 1.798179 | 0.045801 | 1 | 0.019302 | null | dasatinib | Bcr-Abl kinase inhibitor, ephrin inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, src inhibitor, tyrosine kinase inhibitor | ABL1, ABL2, BLK, EPHA2, FGR, FRK, FYN, HCK, KIT, LCK, LYN, PDGFRB, SRC, SRMS, STAT5B, YES1 | hematologic malignancy | chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL) | Cc1nc(Nc2ncc(s2)C(=O)Nc2c(C)cccc2Cl)cc(n1)N1CCN(CCO)CC1, Cc1nc(Nc2ncc(s2)C(=O)Nc2c(C)cccc2Cl)cc(n1)N1CCN(CCO)CC1 | Launched | true | ACH-000965 |
BRD-K49350383-001-14-5 | ACH-000965 | RL952_ENDOMETRIUM | MTS010 | 1 | 0.956357 | 0.495704 | 0.004966 | 0.97393 | 0.024945 | null | thioguanine | purine antagonist | IMPDH1, IMPDH2 | hematologic malignancy | acute myeloid leukemia (AML) | Nc1nc2nc[nH]c2c(=S)[nH]1, Nc1nc2nc[nH]c2c(=S)[nH]1, Nc1nc2nc[nH]c2c(=S)[nH]1 | Launched | true | ACH-000965 |
BRD-K50010139-001-01-5 | ACH-000965 | RL952_ENDOMETRIUM | MTS010 | 1 | -0.02288 | 0.247365 | 0.551969 | 0.435318 | 0.030405 | 0.025374 | poziotinib | EGFR inhibitor | EGFR, ERBB2, ERBB4 | null | null | COc1cc2ncnc(Nc3ccc(Cl)c(Cl)c3F)c2cc1OC1CCN(CC1)C(=O)C=C, COc1cc2ncnc(Nc3ccc(Cl)c(Cl)c3F)c2cc1OC1CCN(CC1)C(=O)C=C | Phase 2 | true | ACH-000965 |
BRD-K50168500-001-07-9 | ACH-000965 | RL952_ENDOMETRIUM | MTS010 | 1 | 0.245712 | 0.517842 | 0.788323 | 0.608638 | 0.062977 | 0.232398 | canertinib | EGFR inhibitor | AKT1, EGFR, ERBB2, ERBB4 | null | null | Fc1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)c(NC(=O)C=C)cc23)cc1Cl | Phase 3 | true | ACH-000965 |
BRD-K51313569-001-07-8 | ACH-000965 | RL952_ENDOMETRIUM | MTS010 | 1 | 1.426605 | 0.112862 | -0.050724 | 1 | 11.192698 | null | palbociclib | CDK inhibitor | CDK4, CDK6 | oncology | breast cancer | CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O, CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O | Launched | true | ACH-000965 |
BRD-K51791723-003-01-7 | ACH-000965 | RL952_ENDOMETRIUM | MTS010 | 1 | 0.045336 | 1.36691 | 0.615106 | 0.677181 | 0.37876 | 0.406037 | P276-00 | CDK inhibitor | CDK1, CDK4, CDK9 | null | null | CN1CC[C@H]([C@@H]1CO)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl | Phase 2 | true | ACH-000965 |
BRD-K51967704-001-03-6 | ACH-000965 | RL952_ENDOMETRIUM | MTS010 | 1 | 0.278781 | 8.637559 | 0.69594 | 0.743987 | 0.319086 | 0.350673 | BIIB021 | HSP inhibitor | HSP90AA1 | null | null | COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C, COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C | Phase 2 | true | ACH-000965 |
BRD-K52313696-001-12-3 | ACH-000965 | RL952_ENDOMETRIUM | MTS010 | 1 | 0.700102 | 0.162846 | 0.048595 | 0.832996 | 0.017871 | null | tacedinaline | HDAC inhibitor | HDAC1 | null | null | CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N, CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N | Phase 3 | true | ACH-000965 |
BRD-K53414658-001-08-2 | ACH-000965 | RL952_ENDOMETRIUM | MTS010 | 1 | 0.551268 | 0.127519 | -0.084271 | 0.790745 | 0.232617 | null | tivozanib | VEGFR inhibitor | FLT1, FLT4, KDR, KIT, PDGFRA, PDGFRB | null | null | COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC | Phase 3 | true | ACH-000965 |
BRD-K53972329-001-07-0 | ACH-000965 | RL952_ENDOMETRIUM | MTS010 | 1 | 1.278477 | 1.388156 | -0.024707 | 1 | 0.054313 | null | ruxolitinib | JAK inhibitor | JAK1, JAK2, JAK3, TYK2 | hematologic malignancy, hematology | myelofibrosis, polycythemia vera | N#CC[C@H](C1CCCC1)n1cc(cn1)-c1ncnc2[nH]ccc12 | Launched | true | ACH-000965 |
BRD-K54256913-001-08-7 | ACH-000965 | RL952_ENDOMETRIUM | MTS010 | 1 | 0.072876 | 7.295083 | 0.868133 | 0.763682 | 0.842768 | 0.861174 | MK-1775 | WEE1 kinase inhibitor | WEE1 | null | null | CN1CCN(CC1)c1ccc(Nc2ncc3c(n2)n(-c2cccc(n2)C(C)(C)O)n(CC=C)c3=O)cc1 | Phase 2 | true | ACH-000965 |
BRD-K54955827-001-02-2 | ACH-000965 | RL952_ENDOMETRIUM | MTS010 | 1 | 0.538102 | 0.410739 | 0.348201 | 0.796757 | 0.168427 | null | niraparib | PARP inhibitor | PARP1 | oncology | primary peritoneal cancer (PPC) | NC(=O)c1cccc2cn(nc12)-c1ccc(cc1)[C@@H]1CCCNC1, NC(=O)c1cccc2cn(nc12)-c1ccc(cc1)[C@@H]1CCCNC1 | Launched | true | ACH-000965 |
BRD-K54997624-001-06-0 | ACH-000965 | RL952_ENDOMETRIUM | MTS010 | 1 | 0.786656 | -3.569946 | -0.005042 | 0.94968 | 0.006017 | null | alpelisib | PI3K inhibitor | PIK3CA, PIK3CB, PIK3CD, PIK3CG | null | null | Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(c1)C(C)(C)C(F)(F)F | Phase 3 | true | ACH-000965 |
BRD-K55187425-236-05-2 | ACH-000965 | RL952_ENDOMETRIUM | MTS010 | 1 | 0.101233 | 0.953241 | 0.776774 | 0.398456 | 0.014393 | 0.018248 | rigosertib | cell cycle inhibitor, PLK inhibitor | PLK1 | null | null | COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1 | Phase 3 | true | ACH-000965 |
BRD-K56981171-001-02-8 | ACH-000965 | RL952_ENDOMETRIUM | MTS010 | 1 | 1.180274 | -1.426155 | -0.228126 | 1 | 0.00185 | null | brigatinib | ALK tyrosine kinase receptor inhibitor, EGFR inhibitor | ALK, EGFR | oncology | non-small cell lung cancer (NSCLC) | COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N1CCN(C)CC1 | Launched | true | ACH-000965 |
BRD-K57080016-001-15-9 | ACH-000965 | RL952_ENDOMETRIUM | MTS010 | 1 | 0.170843 | 0.99636 | 0.742478 | 0.647729 | 0.164032 | 0.249552 | selumetinib | MEK inhibitor | MAP2K1 | null | null | Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO, Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO | Phase 3 | true | ACH-000965 |
BRD-K57169635-001-04-5 | ACH-000965 | RL952_ENDOMETRIUM | MTS010 | 1 | 0.499669 | 0.830221 | 0.492367 | 0.67629 | 0.017565 | null | dacomitinib | EGFR inhibitor | EGFR, ERBB2, ERBB4 | null | null | COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN1CCCCC1 | Phase 3 | true | ACH-000965 |
BRD-K58435339-001-03-0 | ACH-000965 | RL952_ENDOMETRIUM | MTS010 | 1 | 0.296355 | 0.540935 | 0.441961 | 0.638607 | 0.067046 | 0.352796 | AT13387 | HSP antagonist | HSP90AA1 | null | null | CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O, CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O | Phase 2 | true | ACH-000965 |
BRD-K58529924-001-01-5 | ACH-000965 | RL952_ENDOMETRIUM | MTS010 | 1 | 0.651484 | 1.727757 | 0.101049 | 0.833358 | 0.102357 | null | ONC201 | AKT inhibitor, MAP kinase inhibitor | TNFSF10 | null | null | Cc1ccccc1CN1C2=NCCN2C2=C(CN(Cc3ccccc3)CC2)C1=O | Phase 2 | true | ACH-000965 |
BRD-K58550667-001-08-7 | ACH-000965 | RL952_ENDOMETRIUM | MTS010 | 1 | 0.091214 | 5.445003 | 0.813229 | 0.658227 | 0.016246 | 0.016858 | FK-866 | niacinamide phosphoribosyltransferase inhibitor | NAMPT | null | null | O=C(NCCCCC1CCN(CC1)C(=O)c1ccccc1)\C=C\c1cccnc1 | Phase 2 | true | ACH-000965 |
BRD-K59317601-001-05-5 | ACH-000965 | RL952_ENDOMETRIUM | MTS010 | 1 | 0.233563 | 0.081797 | -0.012149 | 0.6167 | 0.077691 | null | MLN0128 | mTOR inhibitor | MTOR, PIK3CA, PIK3CD, PIK3CG | null | null | CC(C)n1nc(-c2ccc3oc(N)nc3c2)c2c(N)ncnc12 | Phase 2 | true | ACH-000965 |
BRD-K59369769-001-22-9 | ACH-000965 | RL952_ENDOMETRIUM | MTS010 | 1 | 0.533039 | 3.704037 | 0.207919 | 0.72031 | 0.029895 | null | tozasertib | Aurora kinase inhibitor, Bcr-Abl kinase inhibitor, FLT3 inhibitor, JAK inhibitor | AURKA, AURKB, AURKC, LCK | null | null | CN1CCN(CC1)c1cc(Nc2cc(C)[nH]n2)nc(Sc2ccc(NC(=O)C3CC3)cc2)n1, CN1CCN(CC1)c1cc(Nc2cc(C)[nH]n2)nc(Sc2ccc(NC(=O)C3CC3)cc2)n1 | Phase 2 | true | ACH-000965 |
BRD-K60866521-001-07-1 | ACH-000965 | RL952_ENDOMETRIUM | MTS010 | 1 | 0.847407 | -1.444653 | 0.011201 | 0.956551 | 0.009546 | null | idelalisib | PI3K inhibitor | PIK3CA, PIK3CB, PIK3CD, PIK3CG | hematologic malignancy | chronic lymphocytic leukemia (CLL) | CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1 | Launched | true | ACH-000965 |
BRD-K60997853-001-02-3 | ACH-000965 | RL952_ENDOMETRIUM | MTS010 | 1 | 0.057188 | 2.017761 | 0.609937 | 0.835706 | 1.873994 | 1.990233 | PHA-848125 | CDK inhibitor, growth factor receptor inhibitor | CDK2, CDK4, CDK7, NTRK1 | null | null | CNC(=O)c1nn(C)c-2c1C(C)(C)Cc1cnc(Nc3ccc(cc3)N3CCN(C)CC3)nc-21 | Phase 2 | true | ACH-000965 |
BRD-K61192372-001-08-9 | ACH-000965 | RL952_ENDOMETRIUM | MTS010 | 1 | 192.809291 | 11.742057 | -0.002331 | 1 | 79,371.828216 | null | capecitabine | DNA synthesis inhibitor, thymidylate synthase inhibitor | TYMS | oncology | breast cancer, colorectal cancer | CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O | Launched | true | ACH-000965 |
BRD-K62008436-001-23-9 | ACH-000965 | RL952_ENDOMETRIUM | MTS010 | 1 | 0.135165 | 5.370759 | 0.77531 | 0.571941 | 0.005124 | 0.005434 | paclitaxel | tubulin polymerization inhibitor | BCL2, MAP2, MAP4, MAPT, NR1I2, TLR4, TUBB, TUBB1 | oncology | ovarian cancer, breast cancer, non-small cell lung cancer (NSCLC) | CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1 | Launched | true | ACH-000965 |
BRD-K62196610-001-01-6 | ACH-000965 | RL952_ENDOMETRIUM | MTS010 | 1 | 0.036547 | 0.657946 | 0.452045 | 0.796562 | 2.014799 | 2.261173 | AVN-944 | inosine monophosphate dehydrogenase inhibitor | IMPDH1, IMPDH2 | null | null | CC[C@H](CC#N)OC(=O)N[C@@H](C)c1cccc(NC(=O)Nc2ccc(-c3cnco3)c(OC)c2)c1 | Phase 2 | true | ACH-000965 |
BRD-K62200014-003-10-5 | ACH-000965 | RL952_ENDOMETRIUM | MTS010 | 1 | 0.788652 | 1.098367 | -0.060739 | 0.997142 | 54.580647 | null | anagrelide | phosphodiesterase inhibitor | PDE3A | hematology, hematologic malignancy | thrombocythemia, myeloproliferative neoplasms | Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl, Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl, Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl | Launched | true | ACH-000965 |
BRD-K62627508-001-01-5 | ACH-000965 | RL952_ENDOMETRIUM | MTS010 | 1 | 1.193442 | 0.63077 | 0.09541 | 1 | 0.286007 | null | idasanutlin | MDM inhibitor | MDM2, TP53 | null | null | COc1cc(ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@@](C#N)([C@H]1c1cccc(Cl)c1F)c1ccc(Cl)cc1F)C(O)=O | Phase 3 | true | ACH-000965 |
BRD-K63712959-001-01-8 | ACH-000965 | RL952_ENDOMETRIUM | MTS010 | 1 | 1.237215 | -0.200989 | -0.129641 | 1 | 0.000789 | null | temoporfin | radical formation stimulant | null | oncology | head and neck squamous cell carcinoma (HNSCC) | Oc1cccc(c1)-c1c2CCc(n2)c(-c2cccc(O)c2)c2ccc([nH]2)c(-c2cccc(O)c2)c2ccc(n2)c(-c2cccc(O)c2)c2ccc1[nH]2 | Launched | true | ACH-000965 |
BRD-K64052750-001-22-5 | ACH-000965 | RL952_ENDOMETRIUM | MTS010 | 1 | 0.372356 | 0.577896 | 0.558281 | 0.737555 | 0.192333 | 2.042392 | gefitinib | EGFR inhibitor | EGFR | oncology | non-small cell lung cancer (NSCLC) | COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1 | Launched | true | ACH-000965 |
BRD-K64881305-001-03-7 | ACH-000965 | RL952_ENDOMETRIUM | MTS010 | 1 | 0.060506 | 2.245275 | 0.683065 | 0.267135 | 0.005137 | 0.00544 | ispinesib | kinesin inhibitor | KIF11 | null | null | CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1 | Phase 2 | true | ACH-000965 |
BRD-K66175015-001-12-4 | ACH-000965 | RL952_ENDOMETRIUM | MTS010 | 1 | 0.273982 | 0.375217 | 0.382466 | 0.634524 | 0.074612 | 0.619163 | afatinib | EGFR inhibitor | EGFR, ERBB2, ERBB4 | oncology | non-small cell lung cancer (NSCLC) | CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1, CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1, CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1 | Launched | true | ACH-000965 |
BRD-K67844266-003-01-9 | ACH-000965 | RL952_ENDOMETRIUM | MTS010 | 1 | 0.12062 | 1.938494 | 0.851681 | 0.519036 | 0.049523 | 0.057103 | pevonedistat | nedd activating enzyme inhibitor | NAE1, UBA3 | null | null | NS(=O)(=O)OC[C@@H]1C[C@H](C[C@@H]1O)n1ccc2c(N[C@H]3CCc4ccccc34)ncnc12 | Phase 2 | true | ACH-000965 |
BRD-K69001009-001-02-8 | ACH-000965 | RL952_ENDOMETRIUM | MTS010 | 1 | 0.727703 | -5.684704 | 0.087618 | 0.814022 | 0.461252 | null | golvatinib | VEGFR inhibitor | KDR, MET | null | null | CN1CCN(CC1)C1CCN(CC1)C(=O)Nc1cc(Oc2ccc(NC(=O)C3(CC3)C(=O)Nc3ccc(F)cc3)c(F)c2)ccn1 | Phase 2 | true | ACH-000965 |
BRD-K69694239-001-02-2 | ACH-000965 | RL952_ENDOMETRIUM | MTS010 | 1 | 0.150359 | 1.231599 | 0.759126 | 0.590357 | 0.092969 | 0.124301 | bardoxolone-methyl | nuclear factor erythroid derived, like (NRF2) activator | PPARG, STAT3 | null | null | COC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2 | Phase 3 | true | ACH-000965 |
BRD-K69776681-001-03-8 | ACH-000965 | RL952_ENDOMETRIUM | MTS010 | 1 | 0.264994 | 0.379771 | -0.123761 | 0.626012 | 0.069419 | 0.506831 | volasertib | PLK inhibitor | PLK1 | null | null | CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O, CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O | Phase 3 | true | ACH-000965 |
BRD-K70301465-001-05-9 | ACH-000965 | RL952_ENDOMETRIUM | MTS010 | 1 | 0.534316 | 0.252495 | 0.286201 | 0.747826 | 0.037285 | null | ibrutinib | Bruton's tyrosine kinase (BTK) inhibitor | BLK, BMX, BTK | hematologic malignancy | chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), Waldenstrom's macroglobulinemia (WM) | Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C, Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C | Launched | true | ACH-000965 |
BRD-K70401845-001-15-7 | ACH-000965 | RL952_ENDOMETRIUM | MTS010 | 1 | 0.312199 | 1.328764 | 0.507851 | 0.728758 | 0.218673 | 0.456926 | erlotinib | EGFR inhibitor | EGFR, NR1I2 | oncology | non-small cell lung cancer (NSCLC), pancreatic cancer | COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC, COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC | Launched | true | ACH-000965 |
BRD-K73838513-003-05-5 | ACH-000965 | RL952_ENDOMETRIUM | MTS010 | 1 | 0.738489 | 5.143194 | 0.284319 | 0.925425 | 0.628207 | null | cinacalcet | calcium channel activator | CASR | endocrinology, nephrology, oncology | hyperparathyroidism, chronic kidney disease (CKD), parathyroid carcinoma, hypercalcemia | C[C@@H](NCCCc1cccc(c1)C(F)(F)F)c1cccc2ccccc12 | Launched | true | ACH-000965 |
BRD-K74514084-003-09-2 | ACH-000965 | RL952_ENDOMETRIUM | MTS010 | 1 | 0.661932 | 0.259646 | 0.037748 | 0.851884 | 0.230202 | null | pazopanib | KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | CSF1R, FGF1, FGFR1, FGFR3, FLT1, FLT4, ITK, KDR, KIT, PDGFRA, PDGFRB, SH2B3 | oncology | renal cell carcinoma (RCC), soft tissue sarcoma (STS) | CN(c1ccc2c(C)n(C)nc2c1)c1ccnc(Nc2ccc(C)c(c2)S(N)(=O)=O)n1, CN(c1ccc2c(C)n(C)nc2c1)c1ccnc(Nc2ccc(C)c(c2)S(N)(=O)=O)n1 | Launched | true | ACH-000965 |
BRD-K75009076-001-02-1 | ACH-000965 | RL952_ENDOMETRIUM | MTS010 | 1 | -0.111495 | 6.364011 | 0.588139 | 0.966765 | 7.685841 | 7.446532 | SCH-900776 | CHK inhibitor | CDK2, CHEK1 | null | null | Cn1cc(cn1)-c1cnn2c(N)c(Br)c(nc12)[C@@H]1CCCNC1, Cn1cc(cn1)-c1cnn2c(N)c(Br)c(nc12)[C@@H]1CCCNC1 | Phase 2 | true | ACH-000965 |
BRD-K76210423-001-01-6 | ACH-000965 | RL952_ENDOMETRIUM | MTS010 | 1 | 1.296182 | 0.26521 | -0.052402 | 1 | 17.826866 | null | resiquimod | toll-like receptor agonist | TLR7, TLR8 | null | null | CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O, CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O | Phase 3 | true | ACH-000965 |
BRD-K76239644-001-02-6 | ACH-000965 | RL952_ENDOMETRIUM | MTS010 | 1 | 0.67147 | 0.295273 | 0.140329 | 0.757583 | 0.001381 | null | BMS-690514 | EGFR inhibitor, VEGFR inhibitor | EGFR, ERBB2, FLT3, KDR | null | null | COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1, COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1 | Phase 2 | true | ACH-000965 |
BRD-K76674262-001-03-3 | ACH-000965 | RL952_ENDOMETRIUM | MTS010 | 1 | 0.120966 | 2.988605 | 0.836384 | 0.490131 | 0.035921 | 0.039409 | homoharringtonine | protein synthesis inhibitor | RPL3 | hematologic malignancy | chronic myeloid leukemia (CML) | COC(=O)C[C@](O)(CCCC(C)(C)O)C(=O)O[C@H]1[C@H]2c3cc4OCOc4cc3CCN3CCC[C@]23C=C1OC | Launched | true | ACH-000965 |
BRD-K76908866-001-07-6 | ACH-000965 | RL952_ENDOMETRIUM | MTS010 | 1 | 0.709129 | 0.452663 | 0.292613 | 0.847035 | 0.057041 | null | CP-724714 | EGFR inhibitor, protein tyrosine kinase inhibitor | ERBB2 | null | null | COCC(=O)NC\C=C\c1ccc2ncnc(Nc3ccc(Oc4ccc(C)nc4)c(C)c3)c2c1 | Phase 2 | true | ACH-000965 |
BRD-K77625799-001-07-7 | ACH-000965 | RL952_ENDOMETRIUM | MTS010 | 1 | 0.357361 | 0.197958 | 0.128631 | 0.79483 | 4.717227 | null | vandetanib | EGFR inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor | EGFR, EPHA1, EPHA10, EPHA2, EPHA3, EPHA4, EPHA5, EPHA6, EPHA7, EPHA8, EPHB1, EPHB2, EPHB3, EPHB4, EPHB6, ERBB2, ERBB3, ERBB4, FLT1, FLT4, KDR, PTK6, RET, SRC, TEK, VEGFA | oncology | medullary thyroid cancer (MTC) | COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1 | Launched | true | ACH-000965 |
BRD-K78431006-001-15-1 | ACH-000965 | RL952_ENDOMETRIUM | MTS010 | 1 | 0.096261 | 4.622593 | 0.581748 | 0.961881 | 6.879873 | 7.205606 | crizotinib | ALK tyrosine kinase receptor inhibitor | ALK, MET | oncology | non-small cell lung cancer (NSCLC) | C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl | Launched | true | ACH-000965 |
BRD-K79254416-001-21-8 | ACH-000965 | RL952_ENDOMETRIUM | MTS010 | 1 | 0.222478 | 0.768621 | 0.782565 | 0.361432 | 0.002327 | 0.005006 | decitabine | DNA methyltransferase inhibitor | DNMT1, DNMT3A | hematologic malignancy, hematology | myelodysplastic diseases (MDS), anemia, chronic myeloid leukemia (CML) | Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1, Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1, Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1 | Launched | true | ACH-000965 |
BRD-K81016934-001-02-0 | ACH-000965 | RL952_ENDOMETRIUM | MTS010 | 1 | 0.912171 | 0.018262 | -0.004801 | 0.957289 | 1.574984 | null | INC-280 | c-Met inhibitor | MET | null | null | CNC(=O)c1ccc(cc1F)-c1cnc2ncc(Cc3ccc4ncccc4c3)n2n1 | Phase 2 | true | ACH-000965 |
BRD-K81418486-001-44-2 | ACH-000965 | RL952_ENDOMETRIUM | MTS010 | 1 | 0.167033 | 1.050866 | 0.777589 | 0.737226 | 0.486322 | 0.716058 | vorinostat | HDAC inhibitor | HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC5, HDAC6, HDAC8, HDAC9 | hematologic malignancy | cutaneous T-cell lymphoma (CTCL) | ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1 | Launched | true | ACH-000965 |
BRD-K81473043-001-19-5 | ACH-000965 | RL952_ENDOMETRIUM | MTS010 | 1 | 0.244476 | 1.427864 | 0.761055 | 0.712635 | 0.01564 | 0.025027 | tanespimycin | HSP inhibitor | HSP90AA1 | null | null | CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O, CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O | Phase 3 | true | ACH-000965 |
BRD-K82135108-001-04-3 | ACH-000965 | RL952_ENDOMETRIUM | MTS010 | 1 | 0.164023 | 9.574145 | 0.712304 | 0.565672 | 0.064608 | 0.067348 | elesclomol | oxidative stress inducer | HSPA1A | null | null | CN(NC(=O)CC(=O)NN(C)C(=S)c1ccccc1)C(=S)c1ccccc1 | Phase 3 | true | ACH-000965 |
BRD-K82746043-001-19-3 | ACH-000965 | RL952_ENDOMETRIUM | MTS010 | 1 | 0.334409 | -0.238569 | -0.159948 | 0.783411 | 0.002673 | null | navitoclax | BCL inhibitor | BCL2, BCL2L1, BCL2L2 | null | null | CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1, CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1 | Phase 2 | true | ACH-000965 |
BRD-K82818427-001-04-8 | ACH-000965 | RL952_ENDOMETRIUM | MTS010 | 1 | 0.509105 | 2.104157 | 0.422578 | 0.723003 | 0.041857 | null | batimastat | matrix metalloprotease inhibitor | ADAM28, ADAMTS5, MMP12, MMP16, MMP2, MMP8 | null | null | CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO, CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO | Phase 3 | true | ACH-000965 |
BRD-K83029223-001-01-3 | ACH-000965 | RL952_ENDOMETRIUM | MTS010 | 1 | 0.088682 | 1.713686 | 0.772031 | 0.324194 | 0.000464 | 0.00052 | litronesib | kinesin-like spindle protein inhibitor | KIF11 | null | null | CCNCCS(=O)(=O)NC[C@]1(SC(NC(=O)C(C)(C)C)=NN1C(=O)C(C)(C)C)c1ccccc1 | Phase 2 | true | ACH-000965 |
BRD-K83988098-001-02-0 | ACH-000965 | RL952_ENDOMETRIUM | MTS010 | 1 | -0.126711 | 0.312813 | 0.280691 | 0.552342 | 0.005884 | 0.002858 | alvespimycin | HSP inhibitor | HSP90AA1 | null | null | CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O, CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O | Phase 2 | true | ACH-000965 |
BRD-K85402309-043-01-9 | ACH-000965 | RL952_ENDOMETRIUM | MTS010 | 1 | 0.697798 | 0.36405 | 0.047446 | 0.887378 | 0.211118 | null | dovitinib | EGFR inhibitor, FGFR inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | CSF1R, EGFR, FGFR1, FGFR2, FGFR3, FLT1, FLT3, FLT4, INSR, KDR, KIT, PDGFRA, PDGFRB | null | null | CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O | Phase 3 | true | ACH-000965 |
BRD-K85606544-001-09-1 | ACH-000965 | RL952_ENDOMETRIUM | MTS010 | 1 | 0.467608 | 1.068236 | 0.333761 | 0.768126 | 0.14712 | 1.906723 | neratinib | EGFR inhibitor | EGFR, ERBB2, KDR | null | null | CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C | Phase 3 | true | ACH-000965 |
BRD-K86118762-001-01-8 | ACH-000965 | RL952_ENDOMETRIUM | MTS010 | 1 | 0.672092 | -1.145885 | 0.132757 | 0.906833 | 0.009258 | null | linsitinib | IGF-1 inhibitor | IGF1R, INSR, INSRR | null | null | C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12, C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12 | Phase 3 | true | ACH-000965 |
BRD-K86972824-001-01-4 | ACH-000965 | RL952_ENDOMETRIUM | MTS010 | 1 | 0.982616 | 0.137093 | -0.008886 | 0.987096 | 0.000027 | null | oltipraz | nuclear factor erythroid derived, like (NRF2) activator | ANG | null | null | Cc1c(ssc1=S)-c1cnccn1, Cc1c(ssc1=S)-c1cnccn1 | Phase 3 | true | ACH-000965 |
BRD-K87737963-001-06-0 | ACH-000965 | RL952_ENDOMETRIUM | MTS010 | 1 | -5.254757 | 1.183333 | 0.174821 | 0.965328 | 99.788137 | null | cyt387 | null | JAK1, JAK2, JAK3 | null | null | O=C(NCC#N)c1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1, O=C(NCC#N)c1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1 | Phase 3 | true | ACH-000965 |
BRD-K87782578-001-01-4 | ACH-000965 | RL952_ENDOMETRIUM | MTS010 | 1 | 0.679977 | 4.574507 | 0.323761 | 0.947152 | 2.013986 | null | AVL-292 | Bruton's tyrosine kinase (BTK) inhibitor | BTK, YES1 | null | null | COCCOc1ccc(Nc2ncc(F)c(Nc3cccc(NC(=O)C=C)c3)n2)cc1 | Phase 2 | true | ACH-000965 |
BRD-K87909389-003-03-4 | ACH-000965 | RL952_ENDOMETRIUM | MTS010 | 1 | 0.188533 | 2.206958 | 0.795199 | 0.576014 | 0.062786 | 0.077804 | alvocidib | CDK inhibitor | CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8, CDK9, EGFR, PYGM | null | null | CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl, CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl | Phase 2 | true | ACH-000965 |
BRD-K88510285-001-17-8 | ACH-000965 | RL952_ENDOMETRIUM | MTS010 | 1 | 0.083554 | 2.55626 | 0.742171 | 0.555247 | 0.022555 | 0.024227 | bortezomib | NFkB pathway inhibitor, proteasome inhibitor | PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9, PSMD1, PSMD2, RELA | hematologic malignancy | multiple myeloma, mantle cell lymphoma (MCL) | CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O | Launched | true | ACH-000965 |
BRD-K89014967-001-04-3 | ACH-000965 | RL952_ENDOMETRIUM | MTS010 | 1 | 0.132312 | 0.532758 | 0.707377 | 0.405688 | 0.009104 | 0.01621 | AS-703026 | MEK inhibitor | MAP2K1, MAP2K2 | null | null | OC[C@@H](O)CNC(=O)c1ccncc1Nc1ccc(I)cc1F | Phase 2 | true | ACH-000965 |
BRD-K92441787-001-04-1 | ACH-000965 | RL952_ENDOMETRIUM | MTS010 | 1 | 0.822343 | 0.215834 | -0.051356 | 0.91709 | 0.153201 | null | bexarotene | retinoid receptor agonist | RXRA, RXRB, RXRG | hematologic malignancy | cutaneous T-cell lymphoma (CTCL) | Cc1cc2c(cc1C(=C)c1ccc(cc1)C(O)=O)C(C)(C)CCC2(C)C | Launched | true | ACH-000965 |
BRD-K92723993-001-17-4 | ACH-000965 | RL952_ENDOMETRIUM | MTS010 | 1 | 1.086252 | 0.054506 | -0.002256 | 1 | 0.000431 | null | imatinib | Bcr-Abl kinase inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor | ABL1, CSF1R, DDR1, KIT, NTRK1, PDGFRA, PDGFRB, RET | hematologic malignancy, oncology | chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), myelodysplastic diseases (MDS), aggressive systemic mastocytosis (ASM), hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans (DFSP), gastrointestinal stromal tumors (GIST) | CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1 | Launched | true | ACH-000965 |
BRD-K95142244-001-01-5 | ACH-000965 | RL952_ENDOMETRIUM | MTS010 | 1 | 0.353822 | 1.687753 | 0.742102 | 0.656501 | 0.057473 | 0.1191 | talazoparib | PARP inhibitor | PARP2 | null | null | Cn1ncnc1[C@@H]1[C@H](Nc2cc(F)cc3c2c1n[nH]c3=O)c1ccc(F)cc1 | Phase 3 | true | ACH-000965 |
BRD-K96123349-236-02-8 | ACH-000965 | RL952_ENDOMETRIUM | MTS010 | 1 | 1.208011 | 0.350225 | 0.001474 | 1 | 1.234778 | null | brequinar | dihydroorotate dehydrogenase inhibitor | DHODH | null | null | Cc1c(nc2ccc(F)cc2c1C(O)=O)-c1ccc(cc1)-c1ccccc1F | Phase 2 | true | ACH-000965 |
BRD-K98572433-001-02-9 | ACH-000965 | RL952_ENDOMETRIUM | MTS010 | 1 | 0.349236 | 0.520922 | 0.465749 | 0.653444 | 0.053901 | 0.538417 | AZD8931 | EGFR inhibitor | EGFR, ERBB2, ERBB3 | null | null | CNC(=O)CN1CCC(CC1)Oc1cc2c(Nc3cccc(Cl)c3F)ncnc2cc1OC | Phase 2 | true | ACH-000965 |
BRD-K99113996-001-02-0 | ACH-000965 | RL952_ENDOMETRIUM | MTS010 | 1 | 0.446479 | 2.730539 | 0.397389 | 0.628552 | 0.009409 | 0.021329 | AZD2014 | mTOR inhibitor | MTOR | null | null | CNC(=O)c1cccc(c1)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C | Phase 2 | true | ACH-000965 |
BRD-K99616396-001-05-1 | ACH-000965 | RL952_ENDOMETRIUM | MTS010 | 1 | 0.92574 | -0.010767 | -0.023805 | 0.962541 | 0.405122 | null | motesanib | KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | FLT1, FLT4, KDR, KIT | null | null | CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12 | Phase 3 | true | ACH-000965 |
BRD-K99749624-001-07-0 | ACH-000965 | RL952_ENDOMETRIUM | MTS010 | 1 | 1.194454 | 0.290321 | -0.027033 | 1 | 7.790355 | null | linifanib | PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | CSF1, CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RET, TEK | null | null | Cc1ccc(F)c(NC(=O)Nc2ccc(cc2)-c2cccc3[nH]nc(N)c23)c1 | Phase 3 | true | ACH-000965 |
BRD-M97302542-001-04-4 | ACH-000965 | RL952_ENDOMETRIUM | MTS010 | 1 | 44.274313 | 0.279308 | -0.002635 | 1 | 343,772,014,938,420,750,000,000 | null | dichloroacetate | pyruvate dehydrogenase kinase inhibitor | PDK1 | null | null | [Na].OC(=O)C(Cl)Cl, [Na].OC(=O)C(Cl)Cl | Phase 3 | true | ACH-000965 |
BRD-A25234499-001-19-1 | ACH-000966 | IGROV1_OVARY | MTS010 | 1 | 1.343959 | -1.773395 | 0.230911 | 1 | 0.022276 | null | aminoglutethimide | glucocorticoid receptor antagonist | CYP11A1, CYP19A1 | endocrinology, oncology | Cushing's syndrome, breast cancer | CCC1(CCC(=O)NC1=O)c1ccc(N)cc1, CCC1(CCC(=O)NC1=O)c1ccc(N)cc1, CCC1(CCC(=O)NC1=O)c1ccc(N)cc1 | Launched | true | ACH-000966 |
BRD-A74914197-001-02-9 | ACH-000966 | IGROV1_OVARY | MTS010 | 1 | 0.396298 | 1.058373 | 0.496088 | 0.639032 | 0.001862 | 0.00823 | pralatrexate | dihydrofolate reductase inhibitor | DHFR, TYMS | hematologic malignancy | peripheral T-cell lymphoma (PTCL) | Nc1nc(N)c2nc(CC(CC#C)c3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)cnc2n1 | Launched | true | ACH-000966 |
BRD-K02113016-001-19-6 | ACH-000966 | IGROV1_OVARY | MTS010 | 1 | 0.406954 | 0.234462 | 0.133796 | 0.650599 | 0.014294 | null | olaparib | PARP inhibitor | PARP1, PARP2 | oncology | ovarian cancer | Fc1ccc(Cc2n[nH]c(=O)c3ccccc23)cc1C(=O)N1CCN(CC1)C(=O)C1CC1, Fc1ccc(Cc2n[nH]c(=O)c3ccccc23)cc1C(=O)N1CCN(CC1)C(=O)C1CC1 | Launched | true | ACH-000966 |
BRD-K02130563-001-11-4 | ACH-000966 | IGROV1_OVARY | MTS010 | 1 | 0.104363 | 0.876543 | 0.802915 | 0.411468 | 0.016025 | 0.020931 | panobinostat | HDAC inhibitor | HDAC1, HDAC2, HDAC3, HDAC4, HDAC6, HDAC7, HDAC8, HDAC9 | hematologic malignancy | multiple myeloma | Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1 | Launched | true | ACH-000966 |
BRD-K03390685-001-01-7 | ACH-000966 | IGROV1_OVARY | MTS010 | 1 | 0.359149 | 3.200051 | 0.507711 | 0.878416 | 1.587644 | 2.358802 | cobimetinib | MEK inhibitor | null | oncology | melanoma | OC1(CN(C1)C(=O)c1ccc(F)c(F)c1Nc1ccc(I)cc1F)[C@@H]1CCCCN1 | Launched | true | ACH-000966 |
BRD-K03406345-001-21-1 | ACH-000966 | IGROV1_OVARY | MTS010 | 1 | 1.378899 | -1.490906 | 0.101337 | 1 | 0.012218 | null | azacitidine | DNA methyltransferase inhibitor | DNMT1, DNMT3A | hematologic malignancy, hematology | myelodysplastic diseases (MDS), anemia, chronic myelomonocytic leukemia (CMMoL) | Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000966 |
BRD-K03449891-001-08-6 | ACH-000966 | IGROV1_OVARY | MTS010 | 1 | 0.38319 | 0.185621 | 0.004404 | 0.681038 | 0.052691 | null | foretinib | VEGFR inhibitor | FLT1, FLT4, KDR, MET | null | null | COc1cc2c(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3F)ccnc2cc1OCCCN1CCOCC1 | Phase 2 | true | ACH-000966 |
BRD-K03765900-001-01-9 | ACH-000966 | IGROV1_OVARY | MTS010 | 1 | 0.109814 | 2.176937 | 0.66648 | 0.652888 | 0.227309 | 0.254735 | XL-647 | EGFR inhibitor, VEGFR inhibitor | EGFR, EPHB4, ERBB2, FLT4, KDR | null | null | COc1cc2c(Nc3ccc(Cl)c(Cl)c3F)ncnc2cc1OC[C@H]1C[C@H]2CN(C)C[C@H]2C1 | Phase 3 | true | ACH-000966 |
BRD-K06814349-304-02-7 | ACH-000966 | IGROV1_OVARY | MTS010 | 1 | 0.462167 | 0.338316 | 0.128839 | 0.786851 | 0.352575 | null | fosbretabulin | tubulin polymerization inhibitor, VE-cadherin antagonist | CDH5 | null | null | COc1ccc(C=Cc2cc(OC)c(OC)c(OC)c2)cc1OP(O)(O)=O, COc1ccc(cc1OP(O)(O)=O)\C=C/c1cc(OC)c(OC)c(OC)c1, COc1ccc(cc1OP(O)(O)=O)\C=C/c1cc(OC)c(OC)c(OC)c1, COc1ccc(C=Cc2cc(OC)c(OC)c(OC)c2)cc1OP(O)(O)=O | Phase 3 | true | ACH-000966 |
BRD-K08109215-001-06-4 | ACH-000966 | IGROV1_OVARY | MTS010 | 1 | 0.58857 | 0.439168 | 0.157897 | 0.733888 | 0.012322 | null | I-BET-762 | bromodomain inhibitor | BRD2, BRD3, BRD4 | null | null | CCNC(=O)C[C@@H]1N=C(c2ccc(Cl)cc2)c2cc(OC)ccc2-n2c(C)nnc12 | Phase 2 | true | ACH-000966 |
BRD-K08542803-001-02-3 | ACH-000966 | IGROV1_OVARY | MTS010 | 1 | -0.233136 | 0.315889 | 0.728591 | 0.475512 | 0.241968 | 0.07204 | gambogic-acid | caspase activator | BCL2 | null | null | CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C, CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C, CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C | Phase 2 | true | ACH-000966 |
BRD-K08547377-001-04-4 | ACH-000966 | IGROV1_OVARY | MTS010 | 1 | 0.223847 | 1.331306 | 0.851189 | 0.566756 | 0.044315 | 0.069217 | irinotecan | topoisomerase inhibitor | TOP1, TOP1MT | oncology | colorectal cancer | CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12 | Launched | true | ACH-000966 |
BRD-K08703257-001-13-9 | ACH-000966 | IGROV1_OVARY | MTS010 | 1 | 0.758299 | 0.6227 | 0.001314 | 0.950644 | 2.363733 | null | 3-amino-benzamide | PARP inhibitor | PARP1 | null | null | NC(=O)c1cccc(N)c1, NC(=O)c1cccc(N)c1 | Phase 2 | true | ACH-000966 |
BRD-K08799216-001-05-3 | ACH-000966 | IGROV1_OVARY | MTS010 | 1 | 0.19149 | 1.300429 | 0.61684 | 0.608773 | 0.091374 | 0.132458 | pelitinib | EGFR inhibitor | EGFR | null | null | CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C | Phase 2 | true | ACH-000966 |
BRD-K09951645-001-11-8 | ACH-000966 | IGROV1_OVARY | MTS010 | 1 | 0.688362 | 0.628113 | 0.046179 | 0.771291 | 0.00579 | null | dabrafenib | RAF inhibitor | BRAF, LIMK1, NEK11, RAF1, SIK1 | oncology | melanoma | CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F, CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F, CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F | Launched | true | ACH-000966 |
BRD-K11267252-001-05-1 | ACH-000966 | IGROV1_OVARY | MTS010 | 1 | 1.060554 | -0.431814 | 0.012528 | 1 | 0.29332 | null | alectinib | ALK tyrosine kinase receptor inhibitor | ALK, MET | oncology | non-small cell lung cancer (NSCLC) | CCc1cc2C(=O)c3c([nH]c4cc(ccc34)C#N)C(C)(C)c2cc1N1CCC(CC1)N1CCOCC1, CCc1cc2C(=O)c3c([nH]c4cc(ccc34)C#N)C(C)(C)c2cc1N1CCC(CC1)N1CCOCC1 | Launched | true | ACH-000966 |
BRD-K11630072-001-13-2 | ACH-000966 | IGROV1_OVARY | MTS010 | 1 | 0.454718 | 4.935969 | 0.430845 | 0.746223 | 0.109263 | 0.17774 | carmofur | thymidylate synthase inhibitor | TYMS | oncology | breast cancer, colorectal cancer | CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O, CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O, CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O | Launched | true | ACH-000966 |
BRD-K12343256-001-14-7 | ACH-000966 | IGROV1_OVARY | MTS010 | 1 | 0.405498 | 3.151966 | 0.450576 | 0.832864 | 0.653329 | 1.108362 | trametinib | MEK inhibitor | MAP2K1, MAP2K2 | oncology | melanoma | CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O | Launched | true | ACH-000966 |
BRD-K13049116-001-04-0 | ACH-000966 | IGROV1_OVARY | MTS010 | 1 | 0.537574 | 0.411497 | 0.299946 | 0.809836 | 0.244443 | null | BMS-754807 | IGF-1 inhibitor | AKT1, IGF1R | null | null | C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1 | Phase 2 | true | ACH-000966 |
BRD-K13390322-001-06-3 | ACH-000966 | IGROV1_OVARY | MTS010 | 1 | 0.095242 | 3.622486 | 0.669327 | 0.73501 | 0.582896 | 0.617911 | AT-7519 | CDK inhibitor | CDK1, CDK2, CDK4, CDK5, CDK6, CDK9 | null | null | Clc1cccc(Cl)c1C(=O)Nc1c[nH]nc1C(=O)NC1CCNCC1 | Phase 2 | true | ACH-000966 |
BRD-K13514097-001-04-6 | ACH-000966 | IGROV1_OVARY | MTS010 | 1 | 0.323563 | 0.153166 | 0.004248 | 0.595778 | 0.005262 | 4.728127 | everolimus | mTOR inhibitor | MTOR | oncology, neurology/psychiatry, genetics, urology | breast cancer, neuroendocrine tumors of pancreatic origin (PNET), renal cell carcinoma (RCC), subependymal giant cell astrocytoma (SEGA), tuberous sclerosis complex (TSC), renal angiomyolipoma | CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO | Launched | true | ACH-000966 |
BRD-K13662825-001-07-5 | ACH-000966 | IGROV1_OVARY | MTS010 | 1 | -0.123583 | 0.325708 | 0.619397 | 0.414444 | 0.014319 | 0.007268 | dinaciclib | CDK inhibitor | CDK1, CDK2, CDK5, CDK9 | null | null | CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(nc12)N1CCCC[C@H]1CCO | Phase 3 | true | ACH-000966 |
BRD-K14109347-001-03-4 | ACH-000966 | IGROV1_OVARY | MTS010 | 1 | 0.118945 | 2.549075 | 0.680107 | 0.741973 | 0.583186 | 0.648776 | LY2603618 | CHK inhibitor | CHEK1 | null | null | Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1, Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1 | Phase 2 | true | ACH-000966 |
BRD-K15179879-001-03-2 | ACH-000966 | IGROV1_OVARY | MTS010 | 1 | 0.14017 | 1.247578 | 0.404114 | 0.499789 | 0.035171 | 0.045784 | carfilzomib | proteasome inhibitor | PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9 | hematologic malignancy | multiple myeloma | CC(C)C[C@H](NC(=O)[C@H](CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1 | Launched | true | ACH-000966 |
BRD-K15600710-066-05-8 | ACH-000966 | IGROV1_OVARY | MTS010 | 1 | 0.089718 | 5.066646 | 0.777775 | 0.708493 | 0.438885 | 0.456348 | obatoclax | BCL inhibitor | BCL2 | null | null | COC1=CC(=N\C\1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1, COC1=CC(=N\C\1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1 | Phase 3 | true | ACH-000966 |
Subsets and Splits
No saved queries yet
Save your SQL queries to embed, download, and access them later. Queries will appear here once saved.